KRAS and non-small cell lung carcinoma: Somatic KEAP1 mutation leads to activation of the NRF2 pathway, and NSCLC patients with KEAP1 mutation in addition to an activating KRAS mutation were demonstrated to have a shorter duration of platinum-based chemotherapy and a worse prognosis than other patients with KRAS-mutant [46].